CVS wins upgrade to buy as analyst sees more upside potential than its peers

Dow Jones

02-14

MW CVS wins upgrade to buy as analyst sees more upside potential than its peers

By Steve Gelsi

Leerink boosts CVS to a 'buy' as the healthcare-company's stock stays hot.

CVS Health Corp.'s stock rose Thursday after the drugstore and healthcare-services company picked up an analyst upgrade on the heels of beating its quarterly profit expectations by a wide margin, and making strides in its pharmacy-benefit-manager business.

CVS stock $(CVS)$ was up 3.5%, on top of a 15% rise in the previous session after posting a stronger-than-expected fourth-quarter profit.

Leerink Partners analyst Michael Cherny raised his rating on CVS to buy from market perform and lifted his price target for the stock by $20 to $75 a share.

CVS is starting to benefit from stabilization in its Aetna health-insurance and pharmacy-benefits businesses, he said.

CVS's earnings projections are "likely driving more upside than downside" against Leerink's performance estimates for the company, he said.

"The stock remains at a discounted level versus historical ranges," Cherny said. "The peer set may offer growth-adjusted valuation that are also appealing, but for CVS, it is closer to the end of its issues than these peers."

Including Thursday's moves, CVS's stock is now up 45.7% in 2025, while the S&P 500 SPX has risen 3.4%.

-Steve Gelsi

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

February 13, 2025 12:05 ET (17:05 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2511786305"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2511786305\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2511786305?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-14 01:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2511786305","market":"other","top_or_hot":-1,"title":"CVS wins upgrade to buy as analyst sees more upside potential than its peers","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW CVS wins upgrade to buy as analyst sees more upside potential than its peers\n</p>\n<p>\n  By Steve Gelsi \n</p>\n<p>\n     Leerink boosts CVS to a 'buy' as the healthcare-company's stock stays hot. \n</p>\n<p>\n     CVS Health Corp.'s stock rose Thursday after the drugstore and healthcare-services company picked up an analyst upgrade on the heels of beating its quarterly profit expectations by a wide margin, and making strides in its pharmacy-benefit-manager business. \n</p>\n<p>\n     CVS stock <a href=\"https://laohu8.com/S/CVS\">$(CVS)$</a> was up 3.5%, on top of a 15% rise in the previous session after posting a stronger-than-expected fourth-quarter profit. \n</p>\n<p>\n     Leerink Partners analyst Michael Cherny raised his rating on CVS to buy from market perform and lifted his price target for the stock by $20 to $75 a share. \n</p>\n<p>\n     CVS is starting to benefit from stabilization in its Aetna health-insurance and pharmacy-benefits businesses, he said. \n</p>\n<p>\n     CVS's earnings projections are \"likely driving more upside than downside\" against Leerink's performance estimates for the company, he said. \n</p>\n<p>\n     \"The stock remains at a discounted level versus historical ranges,\" Cherny said. \"The peer set may offer growth-adjusted valuation that are also appealing, but for CVS, it is closer to the end of its issues than these peers.\" \n</p>\n<p>\n     Including Thursday's moves, CVS's stock is now up 45.7% in 2025, while the S&amp;P 500 SPX has risen 3.4%. \n</p>\n<p>\n     -Steve Gelsi \n</p>\n<p>\n     This content was created by MarketWatch, which is operated by Dow Jones &amp; Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 13, 2025 12:05 ET (17:05 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CVS wins upgrade to buy as analyst sees more upside potential than its peers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCVS wins upgrade to buy as analyst sees more upside potential than its peers\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-02-14 01:05</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW CVS wins upgrade to buy as analyst sees more upside potential than its peers\n</p>\n<p>\n  By Steve Gelsi \n</p>\n<p>\n     Leerink boosts CVS to a 'buy' as the healthcare-company's stock stays hot. \n</p>\n<p>\n     CVS Health Corp.'s stock rose Thursday after the drugstore and healthcare-services company picked up an analyst upgrade on the heels of beating its quarterly profit expectations by a wide margin, and making strides in its pharmacy-benefit-manager business. \n</p>\n<p>\n     CVS stock <a href=\"https://laohu8.com/S/CVS\">$(CVS)$</a> was up 3.5%, on top of a 15% rise in the previous session after posting a stronger-than-expected fourth-quarter profit. \n</p>\n<p>\n     Leerink Partners analyst Michael Cherny raised his rating on CVS to buy from market perform and lifted his price target for the stock by $20 to $75 a share. \n</p>\n<p>\n     CVS is starting to benefit from stabilization in its Aetna health-insurance and pharmacy-benefits businesses, he said. \n</p>\n<p>\n     CVS's earnings projections are \"likely driving more upside than downside\" against Leerink's performance estimates for the company, he said. \n</p>\n<p>\n     \"The stock remains at a discounted level versus historical ranges,\" Cherny said. \"The peer set may offer growth-adjusted valuation that are also appealing, but for CVS, it is closer to the end of its issues than these peers.\" \n</p>\n<p>\n     Including Thursday's moves, CVS's stock is now up 45.7% in 2025, while the S&amp;P 500 SPX has risen 3.4%. \n</p>\n<p>\n     -Steve Gelsi \n</p>\n<p>\n     This content was created by MarketWatch, which is operated by Dow Jones &amp; Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 13, 2025 12:05 ET (17:05 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CVS","symbol_name":"西維斯健康","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2511786305","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2511786305","pubTimestamp":1739466300,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Leerink boosts CVS to a 'buy' as the healthcare-company's stock stays hot.CVS Health Corp.'s stock rose Thursday after the drugstore and healthcare-services company picked up an analyst upgrade on the heels of beating its quarterly profit expectations by a wide margin, and making strides in its pharmacy-benefit-manager business.CVS stock  was up 3.5%, on top of a 15% rise in the previous session after posting a stronger-than-expected fourth-quarter profit.Leerink Partners analyst Michael Cherny raised his rating on CVS to buy from market perform and lifted his price target for the stock by $20 to $75 a share.CVS is starting to benefit from stabilization in its Aetna health-insurance and pharmacy-benefits businesses, he said.CVS's earnings projections are \"likely driving more upside than downside\" against Leerink's performance estimates for the company, he said.\"The stock remains at a discounted level versus historical ranges,\" Cherny said. \"The peer set may offer growth-adjusted valuat","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"CVS":"西维斯健康"},"translate_title":"分析师认为CVS比同行有更大的上涨潜力，因此获得买入评级","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CVS":1},"content_text":"MW CVS wins upgrade to buy as analyst sees more upside potential than its peers\n\n\n  By Steve Gelsi \n\n\n     Leerink boosts CVS to a 'buy' as the healthcare-company's stock stays hot. \n\n\n     CVS Health Corp.'s stock rose Thursday after the drugstore and healthcare-services company picked up an analyst upgrade on the heels of beating its quarterly profit expectations by a wide margin, and making strides in its pharmacy-benefit-manager business. \n\n\n     CVS stock $(CVS)$ was up 3.5%, on top of a 15% rise in the previous session after posting a stronger-than-expected fourth-quarter profit. \n\n\n     Leerink Partners analyst Michael Cherny raised his rating on CVS to buy from market perform and lifted his price target for the stock by $20 to $75 a share. \n\n\n     CVS is starting to benefit from stabilization in its Aetna health-insurance and pharmacy-benefits businesses, he said. \n\n\n     CVS's earnings projections are \"likely driving more upside than downside\" against Leerink's performance estimates for the company, he said. \n\n\n     \"The stock remains at a discounted level versus historical ranges,\" Cherny said. \"The peer set may offer growth-adjusted valuation that are also appealing, but for CVS, it is closer to the end of its issues than these peers.\" \n\n\n     Including Thursday's moves, CVS's stock is now up 45.7% in 2025, while the S&P 500 SPX has risen 3.4%. \n\n\n     -Steve Gelsi \n\n\n     This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 13, 2025 12:05 ET (17:05 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}